Evidence map›Paper›PMID 35386576›Full record

ArticleRespirology case reports2022

First molecular approach to diagnose paediatric pulmonary lophomoniasis: A case series.

Amirmasoud Taheri, Mahdi Fakhar, Maryam Nakhaei, Elham Sadat Banimostafavi, Farzad Masiha, Javad Ghaffari, Soroush Sheydai, Mohammad Sadegh Rezaei, Ali Sharifpour

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. First Report of the Pulmonary ParasiteAdvanced biomedical research · 2025
    Article
  3. Article
  4. Response Comment on "Iranian journal of parasitology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amirmasoud TaheriToxoplasmosis Research Center, Communicable Diseases Institute Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.ORCID https://orcid.org/0000-0002-9499-9593
Mahdi FakharToxoplasmosis Research Center, Communicable Diseases Institute Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.ORCID https://orcid.org/0000-0002-4690-6938
Maryam NakhaeiToxoplasmosis Research Center, Communicable Diseases Institute Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.
Elham Sadat BanimostafaviToxoplasmosis Research Center, Communicable Diseases Institute Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.
Farzad MasihaDepartment of Pediatrics, Pediatric Infectious Diseases Research Center Communicable Diseases Institute, Mazandaran University of Medical Sciences Sari Iran.
Javad GhaffariDepartment of Pediatrics, Pediatric Infectious Diseases Research Center Communicable Diseases Institute, Mazandaran University of Medical Sciences Sari Iran.
Soroush SheydaiToxoplasmosis Research Center, Communicable Diseases Institute Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.
Mohammad Sadegh RezaeiRadiology Department Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.
Ali SharifpourToxoplasmosis Research Center, Communicable Diseases Institute Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences Sari Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prospective study was conducted from 2017 to 2021 at Bouali Hospital in Mazandaran province, Sari, Iran. Out of 58 patients who were enrolled in our study, lophomoniasis was diagnosed in bronchoalveolar lavage fluid of nine patients, for the first time, using an in-house polymerase chain reaction technique. All patients were treated with metronidazole at 7.5 mg/kg/day every 12 h for 14 days. After 6 months of follow-up, symptoms were fully resolved.

Indexed as

Lophomonas blattarumlophomoniasispaediatricsPCR

Identifiers

PMID35386576
PMCPMC8971540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.